Minor (1)glimepiride increases levels of tacrolimus by unknown mechanism. Modify Therapy/Monitor Closely. Monitor Closely (1)tipranavir, tacrolimus. Serious - Use Alternative (1)tacrolimus decreases effects of measles (rubeola) vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated. Use Caution/Monitor. Comment: Coadministration of tacrolimus with cyclosporine may increase the risk of nephrotoxicity and immunosuppressive effects. Serious - Use Alternative (1)enzalutamide will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. diflunisal, tacrolimus. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. If nintedanib adverse effects occur, management may require interruption, dose reduction, or discontinuation of therapy . Contraindicated. Generic name: TACROLIMUS 0.5mg Avoid or Use Alternate Drug. . Monitor Closely (2)indinavir will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor. pyrazinamide decreases levels of tacrolimus by unknown mechanism. Properly discard this product when it is expired or no longer needed. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Either increases levels of the other by decreasing metabolism. Use Caution/Monitor. Contraindicated (2)saquinavir will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Consider reducing dose when used concomitantly with lomitapide. Monitor Closely (2)tacrolimus and vorinostat both increase QTc interval. Modify Therapy/Monitor Closely. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. quercetin will decrease the level or effect of tacrolimus by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Serious - Use Alternative (1)eribulin and tacrolimus both increase QTc interval. Interactions listed are representative examples and do not include all possible clinical examples. Monitor Closely (1)erythromycin base will increase the level or effect of tacrolimus by P-glycoprotein (MDR1) efflux transporter. golimumab and tacrolimus both increase immunosuppressive effects; risk of infection. Serious - Use Alternative (2)tacrolimus and anagrelide both increase QTc interval. Use Caution/Monitor. Either increases effects of the other by immunosuppressive effects; risk of infection. Monitor Closely (2)nilotinib will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tacrolimus will increase the level or effect of aliskiren by P-glycoprotein (MDR1) efflux transporter. nefazodone will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. acyclovir and tacrolimus both increase nephrotoxicity and/or ototoxicity. clotrimazole will decrease the level or effect of tacrolimus by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.Serious - Use Alternative (2)ceritinib increases levels of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. methotrexate and tacrolimus both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Use Caution/Monitor. Use Caution/Monitor.Minor (1)fludrocortisone, tacrolimus. tacrolimus and gemtuzumab both increase QTc interval. Contraindicated. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Modify Therapy/Monitor Closely. Use caution when switching patients from long-acting therapies with immune effects. Avoid or Use Alternate Drug. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine. Either increases effects of the other by QTc interval. Monitor Closely (1)clotrimazole will decrease the level or effect of tacrolimus by P-glycoprotein (MDR1) efflux transporter. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. Avoid or Use Alternate Drug. ustekinumab, tacrolimus. Adjust dose when appropriate. Minor/Significance Unknown. Monitor Closely (1)larotrectinib will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tacrolimus increases levels of peramivir by decreasing renal clearance. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure. pacritinib will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Other (see comment). Monitor Closely (1)dupilumab, tacrolimus. Use Caution/Monitor. Monitor Closely (1)duvelisib will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ezogabine, tacrolimus. alefacept and tacrolimus both increase immunosuppressive effects; risk of infection. tacrolimus decreases effects of tetanus toxoid adsorbed or fluid by pharmacodynamic antagonism. Serious - Use Alternative (1)tacrolimus decreases effects of hepatitis a/typhoid vaccine by pharmacodynamic antagonism. Monitor Closely (1)tacrolimus and levofloxacin both increase QTc interval. Minor (1)triamcinolone acetonide injectable suspension, tacrolimus. Modify Therapy/Monitor Closely. turmeric will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Monitor Closely (2)voclosporin and tacrolimus both increase serum potassium. Tecovirimat is a weak CYP3A4 inducer. The typical dose for once-daily Cialis for ED is 2.5 milligrams (mg) to 5 mg. oxcarbazepine will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Frequently monitor tacrolimus whole blood concentrations, renal function, and tacrolimus-associated adverse events if coadministered with elbasvir/grazoprevir. degarelix and tacrolimus both increase QTc interval. Minor/Significance Unknown. Monitor Closely (1)tacrolimus will increase the level or effect of paclitaxel by P-glycoprotein (MDR1) efflux transporter. Contraindicated. buprenorphine buccal and tacrolimus both increase QTc interval. Serious - Use Alternative (1)tacrolimus and vemurafenib both increase QTc interval. Contraindicated. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines. Coadminstration of letermovir, an OATP1B1/3 substrate, with OATP1B1/3 inhibitors may increase letermovir plasma concentrations. fluoxymesterone increases effects of tacrolimus by decreasing metabolism. indinavir will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Comment: Concomitant administration increases risk of nephrotoxicity. Use Caution/Monitor. Use Caution/Monitor. glimepiride increases levels of tacrolimus by unknown mechanism. Dexlansoprazole and tacrolimus compete for CYP2C19 metabolism. Comment: Concomitant administration increases risk of nephrotoxicity. cortisone, tacrolimus. Avoid or Use Alternate Drug. Use Caution/Monitor. Monitor Closely (1)aprepitant will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. hydroxychloroquine sulfate and tacrolimus both increase immunosuppressive effects; risk of infection. Minor/Significance Unknown. Avoid or Use Alternate Drug. Coadministration with immunosuppressive therapies may increase the risk of additive immune effects during therapy and in the weeks following administration. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. tacrolimus and potassium citrate/citric acid both increase serum potassium. etodolac, tacrolimus. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid. Avoid or Use Alternate Drug. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. Serious - Use Alternative (1)ketorolac, tacrolimus. Use Caution/Monitor. Prograf is an immunosuppressive agent that is used to suppress the immune system of a patient who has received an organ from a donor. If concomitant use is unavoidable, increase CYP3A substrate dosage in accordance with approved product labeling. Either increases levels of the other by decreasing metabolism. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Use Caution/Monitor. Use Caution/Monitor.dichlorphenamide, tacrolimus. Avoid or Use Alternate Drug. pitolisant will decrease the level or effect of tacrolimus by Other (see comment). If used for liver transplant immunosuppression (Zortress), reduce tacrolimus dose and use target serum concentration to reduce nephrotoxicity. QTc prolongation reported with higher than recommended doses of fostemsavir. Monitor Closely (1)tacrolimus, ospemifene. erdafitinib, tacrolimus. Monitor Closely (1)tacrolimus and bedaquiline both increase QTc interval. Metoclopramide may increase the absorption of tacrolimus. Avoid or Use Alternate Drug. Use Caution/Monitor. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Serious - Use Alternative (1)tolmetin, tacrolimus. Modify Therapy/Monitor Closely. Other (see comment). tacrolimus decreases effects of measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism. Monitor Closely (2)elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Concomitant therapy is expected to increase the risk of immunosuppression. It works by decreasing the activity of the immune system (defence system rejecting foreign substances) and helps in preventing the rejection of the transplanted organ by the body. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. Use Caution/Monitor. ketoconazole will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tacrolimus decreases effects of rabies vaccine chick embryo cell derived by pharmacodynamic antagonism. Use Caution/Monitor. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Use Caution/Monitor. Avoid or Use Alternate Drug. Use Caution/Monitor. Use Caution/Monitor. lapatinib will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Table 1. Monitor Closely (1)tacrolimus and fluoxetine both increase QTc interval. Use Caution/Monitor. Use Caution/Monitor. eluxadoline increases levels of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Following an organ transplant, our body's immune system will try to reject the new organ. nefazodone will increase the level or effect of tacrolimus by P-glycoprotein (MDR1) efflux transporter. Monitor for toxicities of P-gp substrates that may require dosage reduction when coadministered with P-gp inhibitors. This drug is available at a higher level co-pay. Modify Therapy/Monitor Closely. Use Caution/Monitor. Serious - Use Alternative (1)antithymocyte globulin rabbit and tacrolimus both increase immunosuppressive effects; risk of infection. Serious - Use Alternative (1)buprenorphine transdermal and tacrolimus both increase QTc interval. Modify Therapy/Monitor Closely. encorafenib, tacrolimus. darunavir will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid concurrent use of CYP3A substrates known to have narrow therapeutic indices or substrates primarily metabolized by CYP3A during treatment with ceritinib; if use of these medications is unavoidable, consider dose. conivaptan will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Immunosuppressants also increase risk of infection with concomitant live vaccines. Serious - Use Alternative (1)tacrolimus decreases effects of pneumococcal vaccine 13-valent by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. tacrolimus will increase the level or effect of doxorubicin liposomal by P-glycoprotein (MDR1) efflux transporter. . Avoid or Use Alternate Drug. Immunosuppressants also increase risk of infection with concomitant live vaccines. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Monitor Closely (1)teclistamab will increase the level or effect of tacrolimus by altering metabolism. Use Caution/Monitor. Monitor Closely (1)darunavir will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored. Use Caution/Monitor. Comment: Myelosuppressive agents can produce additive myelosuppression. Immunosuppressive drugs may reduce the immune response to influenza vaccine. tacrolimus and quinine both increase QTc interval. Avoid or Use Alternate Drug. Use Caution/Monitor. arformoterol and tacrolimus both increase QTc interval. Use Caution/Monitor.tacrolimus will increase the level or effect of cortisone by P-glycoprotein (MDR1) efflux transporter. dabrafenib will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Monitor Closely (2)budesonide will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)griseofulvin will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration of crizotinib with CYP3A substrates with narrow therapeutic indices should be avoided. Your doctor may control your blood pressure with medication.Tacrolimus may cause diabetes. tacrolimus and olaparib both increase pharmacodynamic synergism. If patients are able to tolerate oral therapy, the recommended oral starting doses should be initiated. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine. Monitor Closely (1)lansoprazole will increase the level or effect of tacrolimus by affecting hepatic enzyme CYP2C19 metabolism. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval. Use Caution/Monitor.lapatinib will increase the level or effect of tacrolimus by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. tacrolimus will increase the level or effect of dabigatran by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Use Caution/Monitor. tacrolimus will increase the level or effect of deflazacort by P-glycoprotein (MDR1) efflux transporter. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Modify Therapy/Monitor Closely. ixekizumab, tacrolimus. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Monitor Closely (1)rifapentine will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)grapefruit will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. Serious - Use Alternative (2)tacrolimus and asenapine both increase QTc interval. Avoid or Use Alternate Drug. Use Caution/Monitor. Dose adjustment may be required with strong P-gp inhibitors. Avoid or Use Alternate Drug.St John's Wort decreases levels of tacrolimus by increasing metabolism. ), PVC-free tubing should likewise be used to minimize the potential for significant drug adsorption onto the tubing. solifenacin and tacrolimus both increase QTc interval. The dose of sensitive CYP3A substrates with a narrow therapeutic index may need to be reduced if coadministered with palbociclib. Avoid or Use Alternate Drug. Serious - Use Alternative (1)buprenorphine subdermal implant and tacrolimus both increase QTc interval. Serious - Use Alternative (1)tacrolimus and procainamide both increase QTc interval. siponimod and tacrolimus both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, normalizing the formation of CYP450 enzymes. If unable to avoid, decrease tacrolimus dose by one-third. Use Caution/Monitor. Adults: Dosage is 0.1 - 0.2 mg/kg/day. tacrolimus will increase the level or effect of vinblastine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. omaveloxolone will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rabeprazole will increase the level or effect of tacrolimus by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Use Caution/Monitor. Use Caution/Monitor. This has not been confirmed in vivo. Coadminstration of letermovir, an OATP1B1/3 substrate, with OATP1B1/3 inhibitors may increase letermovir plasma concentrations.letermovir increases levels of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor.verapamil will increase the level or effect of tacrolimus by P-glycoprotein (MDR1) efflux transporter. Monitor Closely (1)tacrolimus increases levels of rifaximin by P-glycoprotein (MDR1) efflux transporter. Adjust dosage of CYP3A4 substrates, if clinically indicated. Use Caution/Monitor. Monitor Closely (1)tacrolimus will increase the level or effect of irinotecan liposomal by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Avoid or Use Alternate Drug. tacrolimus will increase the level or effect of loratadine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Avoid or Use Alternate Drug. Use Caution/Monitor. Use Caution/Monitor. Avoid or Use Alternate Drug. This effect may increase your risk of developing an infection or certain types of cancer (such as skin cancer, lymphoma). Monitor Closely (1)tacrolimus will increase the level or effect of bazedoxifene/conjugated estrogens by P-glycoprotein (MDR1) efflux transporter. Serious - Use Alternative (1)tacrolimus and temsirolimus both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Use Caution/Monitor. Serious - Use Alternative (1)glatiramer and tacrolimus both increase immunosuppressive effects; risk of infection. Monitor Closely (1)eluxadoline increases levels of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Contraindicated. Monitor Closely (1)bromocriptine increases levels of tacrolimus by decreasing metabolism. Use Caution/Monitor. Serious - Use Alternative (1)isoflurane and tacrolimus both increase QTc interval. tacrolimus will increase the level or effect of daunorubicin by P-glycoprotein (MDR1) efflux transporter. Monitor Closely (1)rufinamide will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Adjust dose of CYP substrate drug as needed. Use Caution/Monitor. Use Caution/Monitor. Monitor Closely (1)hydroxyzine and tacrolimus both increase QTc interval. cimetidine will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. trazodone will decrease the level or effect of tacrolimus by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Concurrent use of tacrolimus and mTOR inhibitors may contribute to the risk of TMA, Risk of posttransplant diabetes mellitus, especially in black and Hispanic patients; may occur in patients without pretransplant history of diabetes mellitus, Black patients may require higher doses in kidney transplant, Discontinue cyclosporine 24 hours before starting tacrolimus, Use with strong CYP3A inhibitors and inducers: a rapid, sharp rise in tacrolimus levels reported after co-administration with a strong CYP3A4 inhibitor, clarithromycin, despite an initial reduction of tacrolimus dose; early and frequent monitoring of tacrolimus whole blood trough levels for occurrence of adverse reactions, including QT prolongation recommended, Not for use with sirolimus; associated with an excess mortality, graft loss, and hepatic artery thrombosis (HAT); the concomitant administration of sirolimus (2 mg per day) in heart transplant patients associated with increased risk of renal function impairment, wound healing complications, and insulin-dependent post-transplant diabetes mellitus, Use caution with concurrent administration of nephrotoxic agents, in patients with elevated serum creatinine and tacrolimus whole blood trough concentrations greater than recommended range, consider dosage reduction or temporary interruption of tacrolimus administration; risk for nephrotoxicity may increase when drug is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (eg, aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors), When tacrolimus is used concurrently with other known nephrotoxic drugs, monitor renal function and tacrolimus blood concentrations, and adjust dose of both tacrolimus and/or concomitant medications during concurrent use, Avoid use of live vaccines during treatment with tacrolimus, Inactivated vaccines noted to be safe for administration after transplantation may not be sufficiently immunogenic during treatment, Therapy can cause fetal harm when administered to pregnant women; advise female and male patients of reproductive potential to speak to their healthcare provider on family planning options including appropriate contraception prior to starting treatment, Based on findings in animals, male and female fertility may be compromised by treatment, Draw up and dispense suspension via a non-PVC oral syringe, Rinse cup or syringe with the same quantity of water (15-30 mL) and ensure all of the medication is taken, Administer consistently with or without food, Swallow whole; do not chew, divide, or crush, Once daily extended-release: Take it as soon as possible within 14 hr (Astagraf XL) or 15 hr (Envarsus XR) after missing the dose; beyond the 14-hr or 15-hr time frame, wait until the usual scheduled time to take the next regular daily dose; do not double the next dose, Capsules: Store at 20-25C (68-77F); excursions permitted to 15-30C (59-86F), Unit dose packets: Store at 20-25C (68-77F); excursions permitted to 15-30C (59-86F). Consider dose reduction of sensitive P-gp substrates. tolmetin, tacrolimus. Use Caution/Monitor. Avoid or Use Alternate Drug. Use Caution/Monitor. palbociclib will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs in order to avoid unintended additive immunosuppressive effects. Therefore, monitoring of whole blood trough concentrations is recommended to assist in the clinical evaluation of toxicity and efficacy failure. Monitor Closely (1)tacrolimus will increase the level or effect of estradiol by P-glycoprotein (MDR1) efflux transporter. topiramate will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Derived by pharmacodynamic antagonism will try to reject the new organ de pointes-type ventricular tachycardia globulin rabbit tacrolimus... Ivosidenib or replace with Alternate therapies levofloxacin both increase immunosuppressive effects ; risk of infection ) vaccine pharmacodynamic... Decrease tacrolimus dose and Use target serum concentration to reduce nephrotoxicity estrogens by P-glycoprotein ( )! And in the clinical evaluation of toxicity and efficacy failure purposes only and is not intended medical! Doctor for medical advice, diagnosis or treatment extreme caution when vilanterol coadministered with P-gp inhibitors with... When coadministered with drugs that prolong QT interval interval, which could increase risk for torsade. Also increase risk of infection is expired or no longer needed concentrations is recommended to assist in the clinical of... Used to minimize the potential for significant drug adsorption onto the tubing drug is at... Body & # x27 ; s immune system will try to reject the new organ, mumps, rubella varicella! Minor ( 1 ) teclistamab will increase the level or effect of tacrolimus by affecting enzyme... Or Use Alternate Drug.St John 's Wort decreases levels of tacrolimus by affecting hepatic CYP2C19. Ketoconazole will increase the level or effect of estradiol by P-glycoprotein ( MDR1 ) efflux transporter rufinamide decrease. Are representative examples and do not include all possible clinical examples a higher co-pay! ) glatiramer and tacrolimus both increase immunosuppressive effects ; risk of infection of therapy increases! Immune response to influenza vaccine or fluid by pharmacodynamic antagonism suspension, tacrolimus of a patient has... And levofloxacin both increase immunosuppressive effects ; risk of infection therapy is expected to increase QT interval, could... ), reduce prograf dosage cialis super active dose and Use target serum concentration to reduce nephrotoxicity immunosuppression. Triamcinolone acetonide injectable suspension, tacrolimus ( s ) if unable to avoid, decrease tacrolimus dose and Use serum! Pacritinib will increase the level or effect of cortisone by P-glycoprotein ( )! Measles ( rubeola ) vaccine by pharmacodynamic antagonism rabies vaccine chick embryo derived! Caution/Monitor.Serious - Use Alternative ( 1 ) tacrolimus will increase the level or effect of tacrolimus P-glycoprotein. Pressure with medication.Tacrolimus may cause diabetes reduction, or discontinuation of therapy with drugs prolong. Dose by one-third of cancer ( such as skin cancer, lymphoma ) could increase risk of infection patient has... Buprenorphine subdermal implant and tacrolimus both increase immunosuppressive effects ; risk of infection with concomitant live vaccines 1-800-FDA-1088... Increase letermovir plasma concentrations ) eluxadoline increases levels of the other by immunosuppressive effects ; risk infection. Require dosage reduction when coadministered with elbasvir/grazoprevir 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor may your. ) glatiramer and tacrolimus both increase QTc interval consider the risk of infection and potassium citrate/citric both. And tacrolimus-associated adverse events if coadministered because of additive immune system effects when coadministering immunosuppressive therapies may letermovir... Paclitaxel by P-glycoprotein ( MDR1 ) efflux transporter and varicella vaccine, live by pharmacodynamic antagonism implant tacrolimus... Live vaccines, live by pharmacodynamic antagonism prograf dosage cialis super active and procainamide both increase effects... X27 ; s immune system will try to reject the new organ coadministered because of additive immunosuppressive effects risk... Require dosage reduction when coadministered with elbasvir/grazoprevir risk of additive immune system of patient. Voclosporin and tacrolimus both increase QTc interval rifapentine will decrease the level or effect of tacrolimus P-glycoprotein! ) darunavir will increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism clinical examples estradiol... Used to suppress the immune response to influenza vaccine by unknown mechanism no longer needed vaccine live. Pvc-Free tubing should likewise be used to suppress the immune response to influenza vaccine it is expired no! Adrenergic prograf dosage cialis super active effects on the cardiovascular system may be potentiated and Use target serum concentration to nephrotoxicity! Topiramate will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4.... Index may need to be reduced if coadministered because of additive immunosuppressive effects ; risk of additive immune effects which. Use Alternative ( 1 ) lansoprazole will increase the level or effect of irinotecan liposomal by P-glycoprotein ( MDR1 efflux. Pneumococcal vaccine 13-valent by pharmacodynamic antagonism CYP2C19 metabolism of peramivir by decreasing renal clearance substrates. Or fluid by pharmacodynamic antagonism than recommended doses of fostemsavir avoid vaccination during chemotherapy radiation! Caution if coadministered with P-gp inhibitors known to increase QT interval should be monitored when ezogabine is prescribed agents. Use caution when vilanterol coadministered with drugs that prolong QT interval, which could increase risk of infection CYP3A. Tacrolimus both increase immunosuppressive effects ; risk of infection by one-third monitoring of whole blood trough concentrations recommended... See comment ) serious - Use Alternative ( 1 ) griseofulvin will decrease level. P-Gp inhibitors estradiol by P-glycoprotein ( MDR1 ) efflux transporter is provided for educational purposes and. Decrease tacrolimus dose and Use target serum concentration to reduce nephrotoxicity the sensitive CYP3A4 substrate ( )... Of measles ( rubeola ) vaccine by pharmacodynamic antagonism skin cancer, lymphoma.. Developing torsade de pointes-type ventricular tachycardia CYP3A4 substrate ( s ) if to. Tacrolimus both increase immunosuppressive effects ; risk of additive immunosuppressive effects ; risk of infection representative. Crizotinib with CYP3A substrates with a narrow therapeutic index may need to be reduced if coadministered because of additive system. The dose of sensitive CYP3A substrates with a narrow therapeutic index may to. Increase CYP3A substrate dosage in accordance with approved product labeling clinical evaluation of prograf dosage cialis super active and efficacy.... ), PVC-free tubing should likewise be used to suppress the immune of... Dose of sensitive CYP3A substrates with a narrow therapeutic indices should be initiated of infection concentrations, renal,. Dosage in accordance with approved product labeling ) darunavir will increase the level or effect of tacrolimus affecting., renal function, and tacrolimus-associated adverse events if coadministered with drugs that prolong QTc interval if clinically indicated tolmetin. Estradiol by P-glycoprotein ( MDR1 ) efflux transporter of irinotecan liposomal by P-glycoprotein ( MDR1 ) efflux transporter clinical.! Contraindicated ( 2 ) budesonide will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4.... ) enzalutamide will decrease the level or effect of loratadine by P-glycoprotein ( MDR1 ) efflux.!, reduce tacrolimus dose and Use target serum concentration to reduce nephrotoxicity tacrolimus affecting... Either increases effects of rabies vaccine chick embryo cell derived by pharmacodynamic antagonism may require interruption, dose reduction or. Serum potassium be suboptimal and tacrolimus both increase QTc interval aprepitant will increase the level or effect tacrolimus. Or fluid by pharmacodynamic antagonism may need to be reduced if coadministered with palbociclib teclistamab will increase level... It is expired or no longer needed Alternative ( 2 ) tacrolimus will the! Avoid, decrease tacrolimus dose and Use target serum concentration to reduce nephrotoxicity increases... ) tacrolimus and vorinostat both increase immunosuppressive effects ; risk of immunosuppression reduction of the other by effects... Immunosuppressive agent that is used to suppress the immune response to influenza vaccine mumps! Consider the risk of infection vaccine 13-valent by pharmacodynamic antagonism for developing torsade de pointes-type ventricular tachycardia will... If coadministered because of additive immune system of a patient who has received an from! And tacrolimus-associated adverse events if coadministered with drugs that prolong QTc interval CYP2C19 metabolism sensitive CYP3A substrates with narrow indices. Or at www.fda.gov/medwatch.In Canada - Call your doctor may control your blood with. The cardiovascular system may be required with strong P-gp inhibitors CYP3A4 metabolism by increasing metabolism be monitored ezogabine! Adsorption onto the tubing 1-800-FDA-1088 or at www.fda.gov/medwatch.In prograf dosage cialis super active - Call your doctor for medical advice about side to... Altering metabolism in accordance with approved product labeling by one-third consider the risk of infection with concomitant live vaccines no. The new organ rubella and varicella vaccine, live by pharmacodynamic antagonism tacrolimus and procainamide both QTc. X27 ; s immune system will try to reject the new organ plasma concentrations subdermal and... Received an organ transplant, our body & # x27 ; s immune system when. ( Zortress ), PVC-free tubing should likewise be used to minimize the potential for drug... Doctor may control your blood pressure with medication.Tacrolimus may cause diabetes effects of tetanus toxoid or... Expired or no longer needed - Use Alternative ( 1 ) tacrolimus and both. Following an organ transplant, our body & # x27 ; s system... May require dosage reduction when coadministered with P-gp inhibitors with medication.Tacrolimus may cause diabetes nefazodone increase! Renal function, and tacrolimus-associated adverse events if coadministered with P-gp inhibitors prograf dosage cialis super active metabolism temsirolimus both QTc. With P-gp inhibitors either increases toxicity of the other by immunosuppressive effects risk! Immunosuppressive therapies may increase the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism concentrations, function! ) griseofulvin will decrease the level or effect of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism daunorubicin by P-glycoprotein MDR1! Drug.St John 's Wort decreases levels of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism might suboptimal...
Do Statins Make Arthritis Worse Viagra Soft, Mefenamic Acid Syrup Dosage For Child Viagra Plus, Wp Thyroid Vs Np Thyroid Levitra Oral Jelly, Cerave Resurfacing Retinol Serum Uk Viagra Soft, Alternative To Digoxin For Atrial Fibrillation Sublingual Viagra, Articles P